Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE

Harbor Capital Advisors Inc. lowered its holdings in Haemonetics Corporation (NYSE:HAE) by 51.9% in the fourth quarter, Holdings Channel reports. The firm owned 20,631 shares of the medical instruments supplier’s stock after selling 22,228 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Haemonetics were worth $1,654,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in Haemonetics by 372.8% during the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after buying an additional 1,678,630 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Haemonetics by 4,296.3% during the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after buying an additional 755,592 shares during the last quarter. Norges Bank bought a new position in shares of Haemonetics in the 2nd quarter valued at about $36,822,000. Invenomic Capital Management LP grew its holdings in shares of Haemonetics by 1,691.5% in the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock valued at $24,288,000 after acquiring an additional 470,502 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Haemonetics in the third quarter valued at about $15,703,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Down 0.1%

Shares of HAE stock opened at $56.79 on Friday. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $87.32. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of 15.64, a PEG ratio of 1.11 and a beta of 0.36. The firm’s 50-day moving average is $60.87 and its 200-day moving average is $65.10. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $338.97 million during the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.Haemonetics’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. BTIG Research restated a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Needham & Company LLC lowered Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Citigroup dropped their price objective on Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Finally, Mizuho cut their price objective on Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and an average target price of $83.89.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.